{
    "nctId": "NCT01134497",
    "briefTitle": "Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer",
    "officialTitle": "A Randomised Phase II Study of Carboplatin With or Without the Addition of the ETAR Inhibitor ZD4054 as Treatment for Patients With Metastatic Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "PFS (time to event)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged over 18\n* Histological or cytological diagnosis of metastatic breast cancer, or previous histological diagnosis of breast cancer and evidence of metastatic or locally advanced disease unsuitable for local therapy\n* No more than 2 prior lines of chemotherapy treatment for metastatic breast cancer\n* Life expectancy greater than 12 weeks\n* Patients must have previously received or be ineligible for a taxane\n* Informed written consent\n* Adequate bone marrow and hepatic function\n* Haemoglobin \u2265 9.0 g/dl (if no prior transfusion or transfusion more than 4 weeks previously) or \u2265 10.0 g/dl (transfusion within last 4 weeks), absolute neutrophil count \u2265 1.5 x 109/L, platelets \u2265100 x 109/L\n* Total bilirubin \\< 1.5 x upper normal limit\n* AST and ALT \u2264 2.5 x upper normal limit (or \u2264 5x UNL in the presence of liver metastases)\n* Adequate renal function\n* GFR \u2265 60 mls/min calculated using Wright Formula or measured by EDTA plasma clearance At least one measurable lesion on CT scanning. Disease measurable by other RECIST v1.1 compatible imaging (e.g. MRI, CXR) or clinically measurable will be allowed as long as the same assessment method is used throughout the trial\n* ECOG performance status \u2264 2\n\nExclusion Criteria:\n\n* Previous treatment with platinum based chemotherapy\n* Known brain or leptomeningeal metastases\n* Any co-existing medical conditions that, in the Investigator's judgement, may substantially increase the risk associated with the patient's participation in the study or potentially hamper compliance with the study protocol and follow-up schedule\n* Concomitant medication unsuitable for combination with trial medication\n* Concomitant administration of potent CYP3A inhibitors, specifically: Protease inhibitors (atanazavir, indinavir, nelfinavir, ritonavir, saquinavir), Macrolide antibiotics (clarithromycin, telithromycin), Azole antifungals (ketoconazole, itraconazole, voriconazole), nefazodone",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}